Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 2.36
AVEO's Cash-to-Debt is ranked lower than
70% of the 982 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. AVEO: 2.36 )
Ranked among companies with meaningful Cash-to-Debt only.
AVEO' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.54  Med: 5.28 Max: N/A
Current: 2.36
Equity-to-Asset 0.13
AVEO's Equity-to-Asset is ranked lower than
91% of the 729 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. AVEO: 0.13 )
Ranked among companies with meaningful Equity-to-Asset only.
AVEO' s Equity-to-Asset Range Over the Past 10 Years
Min: -3.21  Med: 0.44 Max: 0.79
Current: 0.13
-3.21
0.79
Piotroski F-Score: 1
Altman Z-Score: -19.22
Beneish M-Score: -1.97
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating Margin % -778.02
AVEO's Operating Margin % is ranked lower than
74% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. AVEO: -778.02 )
Ranked among companies with meaningful Operating Margin % only.
AVEO' s Operating Margin % Range Over the Past 10 Years
Min: -8035.89  Med: -211.41 Max: 20.59
Current: -778.02
-8035.89
20.59
Net Margin % -728.85
AVEO's Net Margin % is ranked lower than
75% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -84.10 vs. AVEO: -728.85 )
Ranked among companies with meaningful Net Margin % only.
AVEO' s Net Margin % Range Over the Past 10 Years
Min: -8277.57  Med: -219.61 Max: 18.59
Current: -728.85
-8277.57
18.59
ROE % -566.48
AVEO's ROE % is ranked lower than
97% of the 906 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. AVEO: -566.48 )
Ranked among companies with meaningful ROE % only.
AVEO' s ROE % Range Over the Past 10 Years
Min: -566.48  Med: -96.32 Max: 20.76
Current: -566.48
-566.48
20.76
ROA % -81.22
AVEO's ROA % is ranked lower than
80% of the 991 Companies
in the Global Biotechnology industry.

( Industry Median: -30.78 vs. AVEO: -81.22 )
Ranked among companies with meaningful ROA % only.
AVEO' s ROA % Range Over the Past 10 Years
Min: -88.25  Med: -52.18 Max: 13.74
Current: -81.22
-88.25
13.74
ROC (Joel Greenblatt) % -173877.91
AVEO's ROC (Joel Greenblatt) % is ranked lower than
98% of the 951 Companies
in the Global Biotechnology industry.

( Industry Median: -362.00 vs. AVEO: -173877.91 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AVEO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -255591.3  Med: -791.02 Max: 689.47
Current: -173877.91
-255591.3
689.47
3-Year Revenue Growth Rate 12.90
AVEO's 3-Year Revenue Growth Rate is ranked higher than
65% of the 528 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. AVEO: 12.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AVEO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -67.4 Max: 12.9
Current: 12.9
0
12.9
3-Year EBITDA Growth Rate -40.00
AVEO's 3-Year EBITDA Growth Rate is ranked lower than
90% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 0.80 vs. AVEO: -40.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
AVEO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -63.15 Max: -2.4
Current: -40
3-Year EPS without NRI Growth Rate -42.90
AVEO's 3-Year EPS without NRI Growth Rate is ranked lower than
88% of the 554 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. AVEO: -42.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
AVEO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -53.7 Max: -3
Current: -42.9
GuruFocus has detected 5 Warning Signs with AVEO Pharmaceuticals Inc $AVEO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AVEO's 30-Y Financials

Financials (Next Earnings Date: 2017-08-04 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:VTL, NAS:DRNA, OTCPK:HSDT, NAS:OMED, NAS:SRNE, NAS:REPH, NAS:PSTI, NAS:VBLT, NAS:FATE, NAS:VVUS, NAS:GEMP, NAS:EVGN, NAS:TRVN, NAS:CRME, NAS:SBPH, NAS:QURE, OTCPK:AAVXF, NAS:AXSM, NAS:MNKD, NAS:CNAT » details
Traded in other countries:VPA.Germany,
Headquarter Location:USA
AVEO Pharmaceuticals Inc is a biopharmaceutical company focused on discovering, developing and commercializing novel cancer therapeutics.

AVEO Pharmaceuticals is a biopharmaceutical company focused on novel cancer therapeutics. Its product candidates are directed against cancer-causing mechanisms found from its own laboratory research as well as general studies. Tivozanib, its main drug candidate, which is currently in a Phase 3 clinical trial, acts as a potent and selective oral inhibitor of vascular growth receptors.

Ratios

vs
industry
vs
history
PB Ratio 34.92
AVEO's PB Ratio is ranked lower than
92% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. AVEO: 34.92 )
Ranked among companies with meaningful PB Ratio only.
AVEO' s PB Ratio Range Over the Past 10 Years
Min: 0.87  Med: 3.08 Max: 34.92
Current: 34.92
0.87
34.92
PS Ratio 44.52
AVEO's PS Ratio is ranked lower than
67% of the 701 Companies
in the Global Biotechnology industry.

( Industry Median: 11.96 vs. AVEO: 44.52 )
Ranked among companies with meaningful PS Ratio only.
AVEO' s PS Ratio Range Over the Past 10 Years
Min: 0.64  Med: 5 Max: 101.36
Current: 44.52
0.64
101.36
Current Ratio 2.52
AVEO's Current Ratio is ranked lower than
67% of the 981 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. AVEO: 2.52 )
Ranked among companies with meaningful Current Ratio only.
AVEO' s Current Ratio Range Over the Past 10 Years
Min: 1.47  Med: 3.4 Max: 9.47
Current: 2.52
1.47
9.47
Quick Ratio 2.52
AVEO's Quick Ratio is ranked lower than
63% of the 980 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. AVEO: 2.52 )
Ranked among companies with meaningful Quick Ratio only.
AVEO' s Quick Ratio Range Over the Past 10 Years
Min: 1.47  Med: 3.4 Max: 9.47
Current: 2.52
1.47
9.47
Days Sales Outstanding 64.19
AVEO's Days Sales Outstanding is ranked higher than
50% of the 625 Companies
in the Global Biotechnology industry.

( Industry Median: 64.26 vs. AVEO: 64.19 )
Ranked among companies with meaningful Days Sales Outstanding only.
AVEO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 3.19  Med: 42.9 Max: 390.8
Current: 64.19
3.19
390.8

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -13.60
AVEO's 3-Year Average Share Buyback Ratio is ranked lower than
56% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. AVEO: -13.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AVEO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -13.9  Med: -9.9 Max: 0
Current: -13.6
-13.9
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 113.50
AVEO's Price-to-Net-Cash is ranked lower than
94% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: 7.66 vs. AVEO: 113.50 )
Ranked among companies with meaningful Price-to-Net-Cash only.
AVEO' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.75  Med: 4.97 Max: 113.5
Current: 113.5
1.75
113.5
Price-to-Net-Current-Asset-Value 37.83
AVEO's Price-to-Net-Current-Asset-Value is ranked lower than
82% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. AVEO: 37.83 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
AVEO' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.42  Med: 3.73 Max: 37.83
Current: 37.83
1.42
37.83
Price-to-Tangible-Book 32.43
AVEO's Price-to-Tangible-Book is ranked lower than
88% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: 4.93 vs. AVEO: 32.43 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
AVEO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.2  Med: 3.25 Max: 32.43
Current: 32.43
1.2
32.43
Price-to-Median-PS-Value 8.73
AVEO's Price-to-Median-PS-Value is ranked lower than
94% of the 667 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. AVEO: 8.73 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AVEO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.15  Med: 1.05 Max: 18.93
Current: 8.73
0.15
18.93
Earnings Yield (Greenblatt) % -12.98
AVEO's Earnings Yield (Greenblatt) % is ranked lower than
77% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -7.96 vs. AVEO: -12.98 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AVEO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -105714.2  Med: -35.6 Max: 48140
Current: -12.98
-105714.2
48140

More Statistics

Revenue (TTM) (Mil) $3.84
EPS (TTM) $ -0.39
Beta1.96
Short Percentage of Float2.38%
52-Week Range $0.50 - 2.22
Shares Outstanding (Mil)110.36
» More Articles for AVEO

Headlines

Articles On GuruFocus.com
Charlie Tian's Interview on The Next Level Show Jun 28 2017 
Paulson Dives Deeper Into Valeant With Increased Holding Jun 27 2017 
US Market Indexes Lower, Technology Stock Volatility a Factor Jun 27 2017 
General Mills to Release 4th-Quarter, Full-Fiscal 2017 Results Jun 27 2017 
Warren Buffett Interprets the State of the Economy on PBS Newshour Jun 27 2017 
Office Space Provider Is a Good Stock to Follow Jun 27 2017 
Don't Lose Your Faith in Cisco Systems Jun 27 2017 
The Future of Value Investing Jun 27 2017 
Quotes From 2 of the World's Greatest Value Investors Jun 27 2017 
Extracts From the Bible of Value Investing Jun 27 2017 

More From Other Websites
Today's Research Reports on Trending Tickers: AVEO Pharmaceuticals and Cara Therapeutics Jun 28 2017
Here's Why AVEO Oncology Rose As Much As 13.8% Today Jun 27 2017
AVEO's Kidney Cancer Candidate Gets CHMP Recommendation Jun 27 2017
AVEO Oncology Announces $14M in Aggregate Gross Proceeds from Hercules Credit Facility and... Jun 27 2017
Biotech Stocks Showing Signs of Resurgence Jun 26 2017
Today's Research Reports on Stocks to Watch: Portola and AVEO Jun 26 2017
AVEO Pharma surges 48% on recommendation for European approval of its cancer drug Jun 23 2017
EU regulators greenlight U.S. biotech Aveo's kidney cancer drug Jun 23 2017
AVEO Oncology Announces Positive CHMP Opinion for Tivozanib as a Treatment of Advanced Renal Cell... Jun 23 2017
AVEO Reaches Enrollment Target in Pivotal Tivozanib Study Jun 21 2017
AVEO Oncology Announces Pivotal Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma Reaches... Jun 20 2017
Why Is AVEO Pharmaceuticals (AVEO) Up 25% Since the Last Earnings Report? Jun 09 2017
AVEO Oncology Announces Phase 1/2 TiNivo Trial of Tivozanib and Opdivo® (nivolumab) in RCC Advances... Jun 08 2017
AVEO Oncology and Biodesix Announce Results from Two Investigator-Sponsored Phase 1 Studies of HGF... Jun 05 2017
AVEO Oncology Announces Completion of a CHMP Oral Explanation for Tivozanib as a Treatment of... May 19 2017
AVEO Announces Appointment of Matthew Dallas as Chief Financial Officer May 16 2017
AVEO Issues Statement Regarding the Passing of Lead Director Henri A. Termeer May 15 2017
AVEO Oncology Announces Receipt of USPTO Notice of Allowance Related to AV-353 May 08 2017
AVEO Pharmaceuticals (AVEO) Q1 Loss Narrower Than Expected May 05 2017
Today's Research Reports on Biotech Stocks to Watch: AVEO Pharmaceuticals and PharmAthene May 05 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}